Company InnoCan Pharma Corporation

INNO

CA45783P1027

Pharmaceuticals

Market Closed - Canadian Securities Exchange Other stock markets 09:42:12 2024-12-04 am EST			5-day change	1st Jan Change
0.2150 ^CAD	0.00%		-6.52%	-30.65%

Nov. 26	InnoCan Pharma Releases Encouraging Results from Study of LPT-CBD on Minipigs	MT
Nov. 26	Innocan Pharma Corporation Announces Encouraging Results from a Safety Assessment Study of LPT-CBD on Minipigs	CI

Business description: InnoCan Pharma Corporation

Innocan Pharma Corporation is an Israel-based company active in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, the Company aims to provide a safe, non-opioid chronic pain management solutions for both animals and humans. To achieve this aim, the Company developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, the Company develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan established a Joint Venture (BI Sky Global Ltd.) that focused on advanced, targeted online sales.

Sales by Activity: InnoCan Pharma Corporation

Fiscal Period: December	2019	2020	2021	2022	2023
Online Sales	-	-	-	-	13.55M
Other Operations	-	-	-	-	109K
Pharmaceuticals	-	8K	196K	2.56M	-

See all business segments

Geographical breakdown of sales: InnoCan Pharma Corporation

Fiscal Period: December	2019	2020	2021	2022	2023
United States	-	-	34K	2.42M	13.55M
Rest of The World	-	-	41K	59K	109K
United Kingdom	-	-	-	83K	-
Poland	-	-	60K	-	-
France	-	-	61K	-	-
Israel	-	8K	-	-	-

See all geographic segments

Managers: InnoCan Pharma Corporation

Director	Title	Age	Since
Nir Avram CTO	Chief Tech/Sci/R&D Officer	71	-
Iris Bincovich CEO	Chief Executive Officer	-	2018-05-30
Nelson Halpern DFI	Director of Finance/CFO	-	2019-02-19
Eyal Kalo CTO	Chief Tech/Sci/R&D Officer	-	2023-04-30
Roni Kamhi COO	Chief Operating Officer	-	2022-08-10

See INNOCAN PHARMA CORPORATION governance

Members of the board: InnoCan Pharma Corporation

Manager	Title	Age	Since
Ron Abraham Mayron CHM	Chairman	60	2019-09-24
Iris Bincovich BRD	Director/Board Member	-	2018-05-30
Ralph Bossino BRD	Director/Board Member	-	2019-09-29
Joshua Lintern BRD	Director/Board Member	37	2019-09-29
Eyal Flom BRD	Director/Board Member	59	2019-09-24
Peter Bloch BRD	Director/Board Member	64	2020-01-21

Composition of the Board of Directors

Shareholders: InnoCan Pharma Corporation

Name	Equities	%	Valuation
Solsken Ltd. 17.72 %	49,726,309	17.72 %	9 M $
Ron Abraham Mayron 2.529 %	7,098,885	2.529 %	1 M $
Iris Bincovich 2.077 %	5,828,010	2.077 %	1 M $
Eyal Flom 0.9097 %	2,553,055	0.9097 %	459 550 $
PP-Asset Management GmbH 0.1881 %	528,000	0.1881 %	95 040 $

List of INNOCAN PHARMA CORPORATION shareholders

Company details: InnoCan Pharma Corporation

InnoCan Pharma Corp.

926-5th Avenue SW Suite 1015

T2P 0N7, Calgary

+403-777-1519

http://www.innocanpharma.com

address InnoCan Pharma Corporation(INNO)

Other Pharmaceuticals

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
INNOCAN PHARMA CORPORATION	0.00%	-6.52%	-32.81%	-74.40%	43.85M
ELI LILLY AND COMPANY	+1.69%	+3.04%	+39.26%	+231.19%	732B
NOVO NORDISK A/S	-0.51%	+4.44%	+12.16%	+119.14%	488B
JOHNSON & JOHNSON	-1.58%	-1.40%	-3.80%	-4.40%	367B
ABBVIE INC.	-0.15%	+0.20%	+26.56%	+52.71%	321B
MERCK & CO., INC.	+1.23%	+0.23%	-1.56%	+38.87%	258B
ROCHE HOLDING AG	+0.04%	+0.67%	+3.21%	-30.84%	231B
NOVARTIS AG	-1.82%	-1.51%	+6.05%	+22.40%	210B
ASTRAZENECA PLC	-1.67%	+0.64%	+3.25%	+26.74%	212B
AMGEN INC.	+0.08%	-0.60%	+2.15%	+37.48%	150B
Average	-0.30%	-0.15%	+5.45%	+41.89%	296.71B
Weighted average by Cap.	-0.27%	+1.24%	+14.97%	+88.16%